Clinical Trial Detail

NCT ID NCT02629809
Title Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

CLL/SLL

Therapies

Cyclophosphamide + Fludarabine + Ibrutinib + Obinutuzumab

Ibrutinib + Obinutuzumab

Ibrutinib

Age Groups: adult senior

No variant requirements are available.